cbdMD, Inc. (AMEX:YCBD) announced the first results from its recently concluded human clinical trial conducted at the University of South Carolina. These studies began in the fall of 2020 and the first results to be reported show the company's proprietary broad spectrum hemp extract reduces pain in healthy adults. The randomized, double blind, placebo controlled study was designed to explore the effects of cbdMD's proprietary broad spectrum cannabinoid blend on sleep, immunity, inflammation, mood, and pain in healthy adult subjects to further support the efficacy of the company's products.

The company and its subsidiary cbdMD Therapeutics, LLC will be releasing further results from the human clinical as they are finalized over the next few weeks and …

Full story available on Benzinga.com